Abstract:Immune checkpoint inhibitors (ICPis) are emerging anti-tumor drugs, with endocrine adverse reactions as its most common adverse drug reactions, and mainly involves multiple endocrine glands, such as glands of thyroid, pituitary, adrenal and pancreas, leading to endocrine dysfunction. If its emergencies can not be correctly identified and prevented in the early stage, it may be life-threatening. Although a number of relevant guidelines/consensuses have been published at home and abroad, there is no consensus on the diagnosis and treatment process of endocrine adverse reactions caused by ICPis in China. In order to standardize and improve the clinical diagnosis and treatment level of relevant departments, we have reviewed and analyzed a number of domestic and international expert consensuses and clinical studies, and formulated this consensus based on integration of the opinions of oncology, endocrinology and nursing experts.
